Proteomic patterns as a diagnostic tool for early-stage cancer

The pace of development in novel technologies that promise improvements in the early diagnosis of disease is truly impressive. One such technology at the forefront of this revolution is mass spectrometry. New capabilities in mass spectrometry have provided the means for the development of proteomics, and the race is on to find innovative ways to apply this powerful technology to solving the problems faced in clinical medicine. One area that has garnered much attention over the past few years is the use of mass spectral patterns for cancer diagnostics.The use of these so-called ‘proteomic patterns’ for disease diagnosis relies fundamentally on the pattern of signals observed within a mass spectrum rather than the more conventional identification and quantitation of a biomarker such as in the case of cancer antigen-125-or prostate-specific antigen. The inherent throughput of proteomic pattern technology enables the analysis of hundreds of clinical samples per day. Currently, there are two primary means by which proteomic patterns can be acquired, surface-enhanced laser desorption/ionization (SELDI) and an electrospray ionization (ESI) method that has been popularized under the name, OvaCheck™. In this review, an historical perspective on the development of proteomic patterns for the diagnosis of early-stage cancers is described. In addition, a critical assessment of the overall technology is presented with an emphasis on the steps required to enable proteomic pattern analysis to become a viable clinical tool for diagnosing early-stage cancers.

[1]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[2]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .

[3]  Teuvo Kohonen,et al.  The self-organizing map , 1990 .

[4]  C. Schaefer,et al.  Analysis of the human serum proteome , 2004, Clinical Proteomics.

[5]  T. Kohonen.  Self-organized formation of topology correct feature maps , 1982 .

[6]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[7]  K. Baggerly,et al.  Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma , 2004, Cancer.

[8]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[9]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[10]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[11]  N. Anderson,et al.  Multi‐component immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome , 2003, Proteomics.

[12]  T. Kohonen.  Self-Organized Formation of Correct Feature Maps , 1982 .

[13]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[14]  T. Kohonen.  Self-organized formation of topographically correct feature maps , 1982 .

[15]  George L. Wright,et al.  SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. , 2002, Expert review of molecular diagnostics.

[16]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[17]  E. Petricoin,et al.  High-resolution serum proteomic features for ovarian cancer detection. , 2004, Endocrine-related cancer.

[18]  Alex Pothen,et al.  Computational protein biomarker prediction: a case study for prostate cancer , 2004, BMC Bioinformatics.

[19]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian Cancer , 2002 .

[20]  O John Semmes,et al.  Serum Protein Profiles to Identify Head and Neck Cancer , 2004, Clinical Cancer Research.

[21]  T. Zhukov,et al.  Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. , 2003, Lung cancer.

[22]  C Kainz.  [Early detection and preoperative diagnosis of ovarian carcinoma]. , 1996, Wiener medizinische Wochenschrift.

[23]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[24]  S. Mahon,et al.  A comprehensive look at the early detection of ovarian cancer. , 2003, Clinical journal of oncology nursing.

[25]  Mark D. Johnson,et al.  Proteome Analysis of DNA Damage-induced Neuronal Death Using High Throughput Mass Spectrometry* , 2004, Journal of Biological Chemistry.

[26]  Ming Zhou,et al.  Cancer diagnosis using proteomic patterns , 2003, Expert review of molecular diagnostics.

[27]  M. Snyder,et al.  Recent developments in analytical and functional protein microarrays. , 2003, Current opinion in molecular therapeutics.

[28]  L. Blumenson,et al.  Serum CA-125 measurements > 65 U/mL. Clinical value. , 1997, The Journal of reproductive medicine.

[29]  Emanuel F. Petricoin,et al.  High-resolution serum proteomic features for ovarian cancer detection. , 2004 .

[30]  J. Klein,et al.  Two-dimensional gel electrophoresis: a fundamental tool for expression proteomics studies. , 2004, Contributions to nephrology.

[31]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[32]  Ian J. Jacobs,et al.  SCREENING FOR OVARIAN CANCER : A PILOT RANDOMISED CONTROLLED TRIAL , 1999 .

[33]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[34]  Thomas P Conrads,et al.  SELDI-TOF MS for diagnostic proteomics. , 2003, Analytical chemistry.

[35]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[36]  Asad Umar,et al.  Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. , 2004, Cancer research.